"The U.S. Food and Drug Administration today approved Vimizim (elosulfase alfa), the first FDA-approved treatment for Mucopolysaccharidosis Type IVA (Morquio A syndrome). Morquio A syndrome is a rare, autosomal recessive lysosomal storage disease "...
For completeness, all major reactions to sulfonamides and to pyrimethamine are included below, even though they may not have been reported with Fansidar (see WARNINGS and PRECAUTIONS: Information For The Patient).
Skin and Miscellaneous Sites Allergic Reactions
Erythema multiforme, Stevens-Johnson syndrome, generalized skin eruptions, toxic epidermal necrolysis, urticaria, serum sickness, pruritus, exfoliative dermatitis, anaphylactoid reactions, periorbital edema, conjunctival and scleral injection, photosensitization, arthralgia, allergic myocarditis, slight hair loss, Lyell's syndrome,
Central Nervous System Reactions
Drug fever, chills, periarteritis nodosa and LE phenomenon have occurred.
The sulfonamides bear certain chemical similarities to some goitrogens, diuretics (acetazolamide and the thiazides), and oral hypoglycemic agents. Diuresis and hypoglycemia have occurred rarely in patients receiving sulfonamides. Cross-sensitivity may exist with these agents. Rats appear to be especially susceptible to the goitrogenic effects of sulfonamides, and long-term administration has produced thyroid malignancies in the species.
Read the Fansidar (sulfadoxine and pyrimethamine) Side Effects Center for a complete guide to possible side effects
There have been reports which may indicate an increase in incidence and severity of adverse reactions when chloroquine is used with Fansidar (sulfadoxine and pyrimethamine) as compared to the use of Fansidar (sulfadoxine and pyrimethamine) alone. Fansidar (sulfadoxine and pyrimethamine) is compatible with quinine and with antibiotics. However, antifolic drugs such as sulfonamides, trimethoprim, or trimethoprim-sulfamethoxazole combinations should not be used while the patient is receiving Fansidar (sulfadoxine and pyrimethamine) for antimalarial prophylaxis. Fansidar (sulfadoxine and pyrimethamine) has not been reported to interfere with antidiabetic agents.
If signs of folic acid deficiency develop, Fansidar (sulfadoxine and pyrimethamine) should be discontinued. When recovery of depressed platelets or white blood cell counts in patients with drug-induced folic acid deficiency is too slow, folinic acid (leucovorin) may be administered in doses of 5 to 15 mg intramuscularly daily for 3 days or longer.
Read the Fansidar Drug Interactions Center for a complete guide to possible interactions
Last reviewed on RxList: 10/10/2008
This monograph has been modified to include the generic and brand name in many instances.
Additional Fansidar Information
Fansidar - User Reviews
Report Problems to the Food and Drug Administration
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.
Find out what women really need.